STAMPEDE Will 'Change Practice' in High-Risk Prostate Cancer

(MedPage Today) -- At the virtual European Society for Medical Oncology meeting, researchers presented a combined analysis from the STAMPEDE platform assessing androgen deprivation therapy (ADT) alone for high-risk non-metastatic prostate cancer...